Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Carcinoma 3Squamous Cell Carcinoma of Head and Neck 2Oligodendroglioma 1Myelodysplastic Syndromes 1Lung Neoplasms 1Hemangioma, Cavernous, Central Nervous System 1Head and Neck Neoplasms 1Glioblastoma 1Cytopenia 1Carcinoma, Squamous Cell 1Carcinoma, Non-Small-Cell Lung 1Astrocytoma 1

Interventions

Temozolomide 111Radiotherapy 60Carboplatin 30Bevacizumab 30Magnetic Resonance Spectroscopy 28Carmustine 28Filgrastim 23Surgical Procedures, Operative 22Irinotecan 22Radiation 17Lomustine 16Vincristine 15Etoposide 15Specimen Handling 13Peripheral Blood Stem Cell Transplantation 13O(6)-benzylguanine 13Radiotherapy, Intensity-Modulated 12Procarbazine 11Erlotinib Hydrochloride 11Cyclophosphamide 11Chemotherapy, Adjuvant 11sargramostim 10Thiotepa 10Cisplatin 10Flucytosine 9Everolimus 9antineoplaston AS 2-1 8antineoplaston A10 8Granulocyte Colony-Stimulating Factor 8Vorinostat 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Astrocytoma × DNA × Clear all
NCT04105374 2026-05-07

Testing the Addition of an Anti-cancer Viral Gene Therapy, Toca 511/Toca FC, to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed Glioblastoma

NRG Oncology

Phase 2/3 Withdrawn
CNS

Astrocytoma, Glioblastoma, Oligodendroglioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡